How NLRP3 inhibitors could extend durability and enhance CV benefits over GLP-1 therapies alone
Product Development
Overwhelming majority of biotechs expect pipeline setbacks; many oppose BIO’s reversal
Politics, Policy & Law
Atlas Venture partner’s views on the capital markets, modality plays and industry efficiency, on The BioCentury Show
Finance
Product Development
Orphan Therapeutics Accelerator will pursue hybrid non-profit, commercial model
Emerging Company Profile
Vancouver-based Reverb is making bispecific antibodies to nab cytokines and deliver them to a desired cell or tissue
Data Byte
Pluvicto’s steep launch appears on track to surpass $1B in sales this year
March decisions also include label extensions for UCB’s Bimzelx and Astellas’ Xtandi. Takeda pulls an application for Adcetris
More than 60% of company’s revenues derived from the U.S.
Discovery & Translation
BioCentury’s roundup of translational innovations
Regulation
A small dataset lacking a randomized control group can be enough when the efficacy signal is big and the unmet need severe
Politics, Policy & Law
A pause would give lobbyists time to reduce harms to biopharma companies
Senators investigating biotech, calling for export restrictions
Deals
Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
Finance
Arch backs immunology/fibrosis start-up; JHU spinout launches with $150M; San Diego-based pair advance clinical plans in oncology and neuroscience
Plus Madrigal’s follow-on is among the year’s largest, and PureTech returns cash to shareholders following Karuna takeout
Biopharma Stock Performers
Use BioCentury's interactive dashboard to view top-performing biopharma stocks for the day and the week.
Product Development
Politics, Policy & Law
Management Tracks
BioCentury ISSN 1097-7201